Table 1 Eligible trials with their inclusion criteria and magnesium regimens as at September 2011
Trial | GA at entry (weeks) | Treatment intent | Magnesium sulphate regimen | Comparator |
|---|---|---|---|---|
Mittendorf 2002[39] | 25 to 33 | Tocolysis (cervical dilatation < 4 cm) or; | 4 g bolus followed by 2 to 3 g/hour maintenance | Alternative tocolytic |
|  |  | Neuroprotection of the fetus/infant/child (dilatation ≥ 4 cm) | 4 g bolus (no repeats) | Placebo |
Rouse 2008[40] | 24 to 32 | Neuroprotection of the fetus/infant/child | 6 g over 20-30 mins followed by 2 g/hr (retreatment permitted) | Placebo |
Crowther 2003[41] | less than 30 | Neuroprotection of the fetus/infant/child | 4 g over 20 mins, then 1 g/hour for up to 24 hours or birth (no repeats) | Placebo |
Marret 2008[42] | less than 33 | Neuroprotection of the fetus/infant/child | 4 g (no repeats) | Placebo |
The Magpie Trial Collaborative Group 2002[43] | less than 37 | Neuroprotection of the pre-eclamptic mother | 4 g over 10-15 mins, then either 1 g/hour for 24 hours, or 5 g every 4 hours IM for 24 hours (no repeats) | Placebo |